Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia

Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy. Although 90% of patients are now long‐term survivors, the remaining 10% have poor outcome predominantly due to drug resistance. In this study, we carried out genome‐wide microRNA (miRNA) microarray analysis on diagnostic bone marrow samples to determine miRNA expression profiles associated with poor outcome in ALL. A reduced expression of MIR335 was identified as the most significant miRNA abnormality associated with poor outcome. It is well known that glucocorticoid (GC) resistance is one of the major reasons contributing to poor outcome. We show that exogenous expression of MIR335 in ALL cells increases sensitization to prednisolone‐mediated apoptosis. Moreover, we demonstrate that MAPK1 is a novel target of MIR335, and that MEK/ERK inhibitor treatment enhanced prednisolone‐induced cell death through the activation of BIM (BCL2L11). These results provide a possible underlying molecular mechanism to explain the association between reduced MIR335 with poor clinical outcome, and suggest that approaches to re‐introduce MIR335 expression or override MAPK1 activity may offer promising therapeutic strategies in the treatment of ALL.

[1]  D. Campana,et al.  Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Armstrong,et al.  miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. , 2008, Blood.

[3]  W. Hop,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[4]  Liang-Hu Qu,et al.  MicroRNA Patterns Associated with Clinical Prognostic Parameters and CNS Relapse Prediction in Pediatric Acute Leukemia , 2009, PloS one.

[5]  Yimin Xiong,et al.  Identification of hsa-miR-335 as a Prognostic Signature in Gastric Cancer , 2012, PloS one.

[6]  T. Yanase,et al.  Modification of glucocorticoid sensitivity by MAP kinase signaling pathways in glucocorticoid-induced T-cell apoptosis. , 2006, Experimental hematology.

[7]  Ronit Vogt Sionov,et al.  Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. , 2008, Advances in cancer research.

[8]  S. Lowe,et al.  The microcosmos of cancer , 2012, Nature.

[9]  A. Zelenetz,et al.  Acute lymphoblastic leukemia. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  A. Borkhardt,et al.  Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. , 1999, Blood.

[11]  W. Gerald,et al.  Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.

[12]  I. Rigoutsos.  New tricks for animal microRNAS: targeting of amino acid coding regions at conserved and nonconserved sites. , 2009, Cancer research.

[13]  J. Martinez-Climent,et al.  Epigenetic regulation of miRNA genes in acute leukemia , 2012, Leukemia.

[14]  M. Relling,et al.  Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. , 2011, Blood.

[15]  F. Chew,et al.  BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia. , 2011, Experimental hematology.

[16]  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998 .

[17]  Andreas Rimner,et al.  MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. , 2011, Genes & development.

[18]  John P A Ioannidis,et al.  Clinical outcome prediction by microRNAs in human cancer: a systematic review. , 2012, Journal of the National Cancer Institute.

[19]  M. Brassesco,et al.  MicroRNA expression and activity in pediatric acute lymphoblastic leukemia (ALL) , 2012, Pediatric blood & cancer.

[20]  Nicholas T. Ingolia,et al.  Mammalian microRNAs predominantly act to decrease target mRNA levels , 2010, Nature.

[21]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.

[22]  Sung-Liang Yu,et al.  MicroRNA signature predicts survival and relapse in lung cancer. , 2008, Cancer cell.

[23]  S. Grant,et al.  MEK Inhibitors Potentiate Dexamethasone Lethality in Acute Lymphoblastic Leukemia Cells through the Pro-apoptotic Molecule BIM , 2009, Leukemia.

[24]  R. Siebert,et al.  Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Kristen M. Jacobsen,et al.  Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia. , 2009, Blood.

[26]  Ling Xu,et al.  A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL , 2011, Human molecular genetics.

[27]  Caifu Chen,et al.  MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia , 2011, Haematologica.

[28]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[29]  F Lampert,et al.  Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. , 1998, Blood.

[30]  C. Schneider,et al.  miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53-dependent stress response. , 2010, Cancer research.

[31]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[32]  R. Pieters,et al.  Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale , 2011, Leukemia.